NASDAQ · Biotechnology
GH Research PLC (GHRS)
$17.53
-5.55%
41
In band
Moving averages
SMA 200$21.65-19.03%
Company profile
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
SectorHealthcare
IndustryBiotechnology
Market cap$1.32B
P/E ratioNone
EPS$-0.99
Beta1.324
Dividend yield0.00%
52-week high$31.44
52-week low$12.04
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 32
VRTX
Vertex Pharmaceuticals Inc
RSI 43
CRSP
CRISPR Therapeutics AG
RSI 27
IOVA
Iovance Biotherapeutics Inc
RSI 31
ANRO
Alto Neuroscience Inc
RSI 52
GPCR
Structure Therapeutics Inc
RSI 25
NTLA
Intellia Therapeutics Inc
RSI 37
NVAX
Novavax Inc
RSI 33
SRPT
Sarepta Therapeutics Inc
RSI 29
MRVI
Maravai LifeSciences Holdings Inc - Class A
RSI 48
RSI alerts for GHRS
An email when GHRS closes below RSI 30 or above 70. Nothing else.
Data last updated 13 November 2026 at 4:31 AM EST